MBOT Quote, Financials, Valuation and Earnings

InfuSystem Holdings, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of 6.19%. Microbot Medical, Inc.'s return on equity of -45.11% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 305.09%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 62.84%. Given that Microbot Medical, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Microbot Medical, Inc. is more attractive than InfuSystem Holdings, Inc..

Microbot Medical, Inc. has a beta of 1.231, which suggesting that the stock is 23.071% more volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Microbot Medical, Inc.'s net income of -$3.6M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 1.31x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -862.39%. Microbot Medical, Inc.'s return on equity of -45.11% beat VolitionRX Ltd.'s return on equity of --.

Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 305.09%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 630.65%. Given that VolitionRX Ltd. has higher upside potential than Microbot Medical, Inc., analysts believe VolitionRX Ltd. is more attractive than Microbot Medical, Inc..

Microbot Medical, Inc. has a beta of 1.231, which suggesting that the stock is 23.071% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Microbot Medical, Inc.'s net income of -$3.6M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 20.63x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of -1037.17%. Microbot Medical, Inc.'s return on equity of -45.11% beat Catheter Precision, Inc.'s return on equity of -192.05%.

Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 305.09%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1781.15%. Given that Catheter Precision, Inc. has higher upside potential than Microbot Medical, Inc., analysts believe Catheter Precision, Inc. is more attractive than Microbot Medical, Inc..

Microbot Medical, Inc. has a beta of 1.231, which suggesting that the stock is 23.071% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than Catheter Precision, Inc. quarterly revenues of $226K. Microbot Medical, Inc.'s net income of -$3.6M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 9.50x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -- compared to Microbot Medical, Inc.'s net margin of 3.93%. Microbot Medical, Inc.'s return on equity of -45.11% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Microbot Medical, Inc. has a consensus price target of $8.75, signalling upside risk potential of 305.09%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 119.3%. Given that Microbot Medical, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Microbot Medical, Inc. is more attractive than Xtant Medical Holdings, Inc..

Microbot Medical, Inc. has a beta of 1.231, which suggesting that the stock is 23.071% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Microbot Medical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Microbot Medical, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Microbot Medical, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Microbot Medical, Inc.'s net income of -$3.6M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Microbot Medical, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 67.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Microbot Medical, Inc. is -- versus 0.75x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.